Storia in 2 fonti

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Raccontata da

medpagetoday.com

morningstar.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo1 mese fa

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Questo articolo non è rilevante per Warptech Tech News — è medico/pharma (approvazione FDA di un farmaco oncologico), non tech/AI/business. Puoi mandarmi un articolo tech-relato da riassumere secondo le regole editoriali?

originale

morningstar.com1 mese fa

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient…

TRUQAP won FDA approval for PTEN-deficient metastatic prostate cancer with 19% risk reduction—first targeted therapy available. Companion diagnostic approval marks precision medicine maturity: genomic testing bundled with therapy now reshapes oncology development and reimbursement.

Leggi questa versione →

Timeline cronologica

venerdì 12 giugno 2026·medpagetoday.com
FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting
Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors
sabato 13 giugno 2026·morningstar.com
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive…
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient…

Timeline cronologica

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive…